Literature DB >> 25844400

IPEX Syndrome, FOXP3 and Cancer.

Runhua Liu1, Silin Li2, Wei-Hsiung Yang3, Lizhong Wang.   

Abstract

In this review, we introduce the IPEX syndrome and its relationship with germline mutations of the FOXP3 gene. We then describe the multiple functional roles of FOXP3 in regulatory T cells and epithelial cells as well as in IPEX syndrome and tumor progression. Potential mechanisms of FOXP3 inactivation and transcriptional regulation are discussed with recent advances. Finally, we point out current issues and a potential FOXP3-mediated therapeutic strategy as well as the reactivation of FOXP3 in patients with IPEX syndrome and cancer.

Entities:  

Keywords:  Cancer; FOXP3; IPEX; Syndrome; Tumor suppressors

Year:  2013        PMID： 25844400      PMCID： PMC4383293          DOI： 10.13188/2380-6036.1000001

Source DB:  PubMed          Journal:  J Syndr


  82 in total

1.  Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1.

Authors:  Masahiro Ono; Hiroko Yaguchi; Naganari Ohkura; Issay Kitabayashi; Yuko Nagamura; Takashi Nomura; Yoshiki Miyachi; Toshihiko Tsukada; Shimon Sakaguchi
Journal:  Nature       Date:  2007-03-21       Impact factor: 49.962

2.  A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16.

Authors:  Edwin R Smith; Christelle Cayrou; Rong Huang; William S Lane; Jacques Côté; John C Lucchesi
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

3.  Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells.

Authors:  Ye Zheng; Steven Z Josefowicz; Arnold Kas; Tin-Tin Chu; Marc A Gavin; Alexander Y Rudensky
Journal:  Nature       Date:  2007-01-21       Impact factor: 49.962

4.  Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans.

Authors:  Stanley Hooker; Wenndy Hernandez; Hankui Chen; Christiane Robbins; Jada Benn Torres; Chiledum Ahaghotu; John Carpten; Rick A Kittles
Journal:  Prostate       Date:  2010-02-15       Impact factor: 4.104

5.  FOXP3 germline polymorphisms are not associated with risk of breast cancer.

Authors:  Leon Raskin; Gad Rennert; Stephen B Gruber
Journal:  Cancer Genet Cytogenet       Date:  2009-04-01

6.  FoxP3 maintains Treg unresponsiveness by selectively inhibiting the promoter DNA-binding activity of AP-1.

Authors:  Sang-Myeong Lee; Beixue Gao; Deyu Fang
Journal:  Blood       Date:  2008-01-25       Impact factor: 22.113

7.  FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease.

Authors:  Bin Li; Arabinda Samanta; Xiaomin Song; Kathryn T Iacono; Patrick Brennan; Talal A Chatila; Giovanna Roncador; Alison H Banham; James L Riley; Qiang Wang; Yuan Shen; Sandra J Saouaf; Mark I Greene
Journal:  Int Immunol       Date:  2007-06-22       Impact factor: 4.823

8.  Clinical significance of FOXP3 expression in human gliomas.

Authors:  L Wang; B Zhang; X Xu; S Zhang; X Yan; F Kong; X Feng; J Wang
Journal:  Clin Transl Oncol       Date:  2013-04-12       Impact factor: 3.405

9.  Transcription factor Foxp3 and its protein partners form a complex regulatory network.

Authors:  Dipayan Rudra; Paul deRoos; Ashutosh Chaudhry; Rachel E Niec; Aaron Arvey; Robert M Samstein; Christina Leslie; Scott A Shaffer; David R Goodlett; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2012-08-26       Impact factor: 25.606

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307
View more
  2 in total

1.  FOXP3 expression is modulated by TGF‑β1/NOTCH1 pathway in human melanoma.

Authors:  Eva Skarmoutsou; Valentina Bevelacqua; Fabio D' Amico; Angela Russo; Demetrios A Spandidos; Aurora Scalisi; Grazia Malaponte; Claudio Guarneri
Journal:  Int J Mol Med       Date:  2018-04-04       Impact factor: 4.101

2.  Gastric Adenocarcinoma in the Setting of IPEX Syndrome.

Authors:  David Steffin; Saleh Bhar; Douglas S Fishman; Nicholas L Rider; Bindi Naik-Mathuria; Caridad Martinez; Rajkumar Venkatramani
Journal:  Case Reports Immunol       Date:  2021-06-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.